StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This is an open label, interventional, randomized phase II trial comparing StemRegenin-1
(SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord
blood (standard of care arm) transplantation after a myeloablative CY/FLU/TBI conditioning.
A 2:1 randomization will be employed with a higher chance of being assigned to the
experimental arm.